Investigational drug · Phase 3
64Cu-SAR-bisPSMA
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Prostate Cancer, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
6
Any phase or sponsor naming "64Cu-SAR-bisPSMA"
First trial start
2021
Aug 11, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "64Cu-SAR-bisPSMA", any sponsor or status.
Conditions studied
As listed on its trial records.
- Prostate Cancer
- Prostatic Neoplasms, Castration-Resistant
- Prostatic Neoplasms
- Prostate Cancer Patients With Detectable PSA Following Prostatectomy
- Prostate Cancer Recurrent
- Prostate Cancer Patients Who Have Brachytherapy Seed Implant
- Prostate Cancer Patients Treated by Radiotherapy
- Cryotherapy
Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "64Cu-SAR-bisPSMA" as an intervention, largest first.
- Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical ProstatectomyPivotal-lookingRecruiting
Clarity Pharmaceuticals LtdIndustry
NCT06056830 · 383 participants (planned) · Start Dec 21, 2023 · Primary completion Sep 2026
Drug: 64Cu-SAR-bisPSMA · For: Prostate Cancer; Prostatic Neoplasms
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 34 sites in all
- 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate CancerPivotal-lookingActive, not recruiting
Clarity Pharmaceuticals LtdIndustry
NCT06970847 · 220 participants (planned) · Start May 16, 2025 · Primary completion Dec 31, 2026
Drug: 64Cu-SAR-bisPSMA · For: Prostate Cancer; Prostate Cancer Patients With Detectable PSA Following Prostatectomy; Prostate Cancer Recurrent and 3 more
Sites: Irvine, California; Los Angeles, California; Montebello, California · 22 sites in all
Clarity Pharmaceuticals LtdIndustry
NCT04868604 · 54 participants (planned) · Start Aug 11, 2021 · Primary completion Sep 2026
Drug: 64Cu-SAR-bisPSMA; 67Cu-SAR-bisPSMA · For: Prostatic Neoplasms, Castration-Resistant
Sites: Stanford, California; River Ridge, Louisiana; Grand Rapids, Michigan · 7 sites in all
- 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)Completed
Clarity Pharmaceuticals LtdIndustry
NCT05249127 · 52 participants · Start Apr 11, 2022 · Primary completion Aug 8, 2023
Drug: 64Cu-SAR-bisPSMA · For: Biochemical Recurrence of Malignant Neoplasm of Prostate
Sites: Los Angeles, California; Omaha, Nebraska; Albuquerque, New Mexico · 5 sites in all
St Vincent's Hospital, SydneyAcademic, hospital or other
NCT06907641 · 50 participants · Start Nov 21, 2024 · Primary completion Sep 3, 2025
Drug: 64Cu-SAR-bisPSMA · For: Prostate Cancer (Post Prostatectomy)
Sites: Darlinghurst, Australia
Clarity Pharmaceuticals LtdIndustry
NCT04839367 · 30 participants · Start Jul 13, 2021 · Primary completion Oct 19, 2022
Drug: 64Cu-SAR-bisPSMA · For: Prostatic Neoplasms
Sites: Kingswood, Australia; Sydney, Australia; Murdoch, Australia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Prostate Cancer
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials
Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
- Leuprorelin acetateLeuprolide Open Label, DKF-MA102Phase 33 trials
Pfizer · Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
- MevrometostatPF-06821497Phase 33 trials
Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer
- 177Lu-NYM032Phase 32 trials
Norroy Bioscience Co., LTD · Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.